Agarwal Neeraj, Prchal Josef T
Division of Hematology and Oncology, University of Utah School of Medicine and Veterans Affairs Hospital, Salt Lake City, Utah, USA.
Acta Haematol. 2009;122(2-3):103-8. doi: 10.1159/000243794. Epub 2009 Nov 10.
Mild-to-moderate anemia often develops in the setting of acute or chronic immune activation and is termed anemia of chronic disease (ACD) or anemia of inflammation. Anemia of chronic disease is the second most common type of anemia (after anemia of iron deficiency) and results in increased morbidity and mortality of the underlying disease. Anemia of chronic disease is mediated by inflammatory cytokines and is characterized by low serum iron (hypoferremia) and often increased reticuloendothelial stores of iron. Hepcidin is the master regulator of iron homeostasis and its synthesis is inhibited by iron deficiency and stimulated by inflammation. The serum hepcidin level is useful in identifying iron deficiency in patients with ACD. Successful treatment of the underlying disease improves ACD. If that is not possible and if anemia is symptomatic, treatment with erythropoietic agents, supplemented with iron if necessary, is helpful in many cases.
轻至中度贫血常发生于急性或慢性免疫激活的情况下,被称为慢性病贫血(ACD)或炎症性贫血。慢性病贫血是第二常见的贫血类型(仅次于缺铁性贫血),会导致基础疾病的发病率和死亡率增加。慢性病贫血由炎性细胞因子介导,其特征是血清铁水平低(低铁血症),且网状内皮系统铁储存常常增加。铁调素是铁稳态的主要调节因子,其合成受缺铁抑制,受炎症刺激。血清铁调素水平有助于识别ACD患者的缺铁情况。成功治疗基础疾病可改善ACD。如果无法做到这一点,且贫血有症状,在许多情况下,使用促红细胞生成剂治疗,并在必要时补充铁剂会有帮助。